Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan

被引:280
作者
Ripamonti, C. I. [1 ]
Maniezzo, M. [2 ]
Campa, T. [1 ]
Fagnoni, E. [1 ]
Brunelli, C. [1 ]
Saibene, G. [3 ]
Bareggi, C. [1 ]
Ascani, L. [3 ]
Cislaghi, E. [2 ]
机构
[1] Natl Canc Inst, IRCCS Fdn, Palliat Care Unit Pain Therapy & Rehabil, I-20133 Milan, Italy
[2] Natl Canc Inst, IRCCS Fdn, Consultant Dent Team, I-20133 Milan, Italy
[3] Natl Canc Inst, IRCCS Fdn, Hosp Pharm, I-20133 Milan, Italy
关键词
LONG-TERM EFFICACY; SKELETAL COMPLICATIONS; ZOLEDRONIC ACID; MULTIPLE-MYELOMA; BREAST-CANCER; DOUBLE-BLIND; CLINICAL-FEATURES; AMERICAN-SOCIETY; RANDOMIZED-TRIAL; PHASE-III;
D O I
10.1093/annonc/mdn526
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Screening of the oral cavity and dental care was suggested as mandatory preventive measures of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BPs). We investigated the occurrence of ONJ before and after implementation of dental preventive measures when starting BP therapy. Patients and methods: Since April 2005, 154 consecutive patients treated with BPs (POST-Group) have undergone a baseline mouth assessment (dental visit +/- orthopantomography of the jaws) to detect potential dental conditions and dental care if required. A retrospective review was also conducted of all consecutive cancer patients with bone metastases (PRE-Group) and treated for the first time with BPs from January 1999 to April 2005 in our clinic without receiving any preventive measure. Incidence proportion and incidence rate (IR) were used to estimate the incidence of ONJ. Results: Among the study population (966 patients; male/female = 179/787), 73% had breast cancer. 25% of patients were given zoledronic acid (ZOL), 62% pamidronate (PAM), 8% PAM followed by ZOL and 5% clodronate. ONJ was observed in 28 patients (2.9%); we observed a reduction in the incidence of ONJ from 3.2% to 1.3%, when comparing-025EFpre and post-implementation of preventive measures programme. Considering the patients exposed to ZOL, the performance of a dental examination and the application of preventive measures led to a sustained reduction in ONJ IR (7.8% in the PRE-Group versus 1.7% in the POST-Group; P = 0.016), with an IR ratio of 0.30 (95% confidence interval 0.03-1.26). Conclusions: ONJ is a manageable and preventable condition. Our data confirm that the application of preventive measures can significantly reduce the incidence of ONJ in cancer patients receiving BPs therapy. Dental exams combined to the identification of patients at risk in cooperation with the Dental Team can improve outcomes and increase the number of ONJ-free patients.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 36 条
[1]   Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].
Aapro, M. ;
Abrahamsson, P. A. ;
Body, J. J. ;
Coleman, R. E. ;
Colomer, R. ;
Costa, L. ;
Crino, L. ;
Dirix, L. ;
Gnant, M. ;
Gralow, J. ;
Hadji, P. ;
Hortobagyi, G. N. ;
Jonat, W. ;
Lipton, A. ;
Monnier, A. ;
Paterson, A. H. G. ;
Rizzoli, R. ;
Saad, F. ;
Thuerlimann, B. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :420-432
[2]   Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[3]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[4]   American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].
Berenson, JR ;
Hillner, BE ;
Kyle, RA ;
Anderson, K ;
Lipton, A ;
Yee, GC ;
Biermann, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736
[5]   International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients [J].
Body, Jean-Jacques ;
Coleman, Rob ;
Clezardin, Philippe ;
Ripamonti, Carla ;
Rizzoli, Rene ;
Aapro, Matti .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) :852-858
[6]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[7]   Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176
[8]  
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO
[9]  
2-Z
[10]  
Durie BGM, 2005, NEW ENGL J MED, V353, P99